# EDGAR Filing Document

**Accession Number:** 0000748592
**File Stem:** 0001641172-25-015240
**Filing Date:** 2025-6
**Character Count:** 2232
**Document Hash:** 558b40e9c4699844a764167136665d05
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-015240.hdr.sgml**: 20250718

**ACCESSION NUMBER**: 0001641172-25-015240

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ernexa Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0000748592
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 311103425
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1035 CAMBRIDGE STREET
- **STREET 2:** SUITE 18A
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** (617) 798-6700

**MAIL ADDRESS:**
- **STREET 1:** 10531 4S COMMONS DRIVE
- **STREET 2:** SUITE 166-550
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eterna Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20221017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brooklyn ImmunoTherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NTN BUZZTIME INC
- **DATE OF NAME CHANGE:** 20051230

**Ernexa Therapeutics Inc.**

**1035 Cambridge Street, Suite 18A**

**Cambridge, MA 02141**

June 16, 2025

Securities and Exchange Commission

Division of Corporation Finance

100 F Street N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | **Ernexa Therapeutics Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **Filed June 11, 2025** |
|  | **File No. 333-287954** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Ernexa Therapeutics Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, June 18, 2025, or as soon as practicable thereafter.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Ernexa Therapeutics Inc. | Ernexa Therapeutics Inc. |
| By: | */s/ Sandra Gurrola* |
|  | Sandra Gurrola |
|  | Senior Vice President, Finance |

---